Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice-Reference-Cited by-同舟云学术

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

Published:2022-09 Issue: Volume:63 Page:101533
ISSN:2212-8778
Container-title:Molecular Metabolism
language:en
Short-container-title:Molecular Metabolism

Author:

Knerr Patrick J.,Mowery Stephanie A.,Douros Jonathan D.,Premdjee Bhavesh,Hjøllund Karina Rahr,He Yantao,Kruse Hansen Ann Maria,Olsen Anette K.,Perez-Tilve Diego,DiMarchi Richard D.,Finan Brian^ORCID

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology

Reference75 articles.

1. Drug therapy in obesity: a review of current and emerging treatments;Williams;Diabetes Therapy,2020

2. Anti-obesity therapy: from rainbow pills to polyagonists;Müller;Pharmacological Reviews,2018

3. The new era of drug therapy for obesity: the evidence and the expectations;Jones;Drugs,2015

4. Liraglutide for weight management: a critical review of the evidence;Mehta;Obesity Science and Practice,2017

5. Once-weekly semaglutide in adults with overweight or obesity;Wilding;New England Journal of Medicine,2021

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isoquinoline small molecule ligands are agonists and probe-dependent allosteric modulators of the glucagon subfamily of GPCRs;Biochemical Pharmacology;2024-11

2. Experimental colonization with H. hepaticus, S. aureus and R. pneumotropicus does not influence the metabolic response to high-fat diet or incretin-analogues in wildtype SOPF mice;Molecular Metabolism;2024-09

3. Effects of Once-Weekly Subcutaneous Retatrutide on Weight and Metabolic Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Metabolism Open;2024-09

4. Tirzepatide protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via PI3K/Akt signaling;Peptides;2024-08

5. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide;Cardiovascular Diabetology;2024-07-10